BOTOX ONE Trademark

Trademark Overview


On Tuesday, November 9, 2021, a trademark application was filed for BOTOX ONE with the United States Patent and Trademark Office. The USPTO has given the BOTOX ONE trademark a serial number of 97115552. The federal status of this trademark filing is REGISTERED as of Tuesday, December 12, 2023. This trademark is owned by Allergan, Inc.. The BOTOX ONE trademark is filed in the Advertising, Business and Retail Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Promoting healthcare professionals' awareness of the benefits of botulinum toxin and dissemination of advertisements and consumer product information relating to botulinum toxin via print, audio, video, digital, on-line medium, and electronic mail; Providing business information about the administration of patient reimbursement programs designed to assist patients regarding medical treatment payment plan options; assistance to patients regarding treatment payment plan options, namely, business administration of patient reimbursement programs; providing a website via a global computer network featuring consumer information and comprehensive content being consumer product information in the fields of neurology, dermatology and urology; distribution of samples for trial purposes in the field of neurology, dermatology and urology

Providing resources in the nature of health information for healthcare professionals relating to all approved indications of therapeutic treatments and injection instruction in the fields of neurology and urology
botox one

General Information


Serial Number97115552
Word MarkBOTOX ONE
Filing DateTuesday, November 9, 2021
Status700 - REGISTERED
Status DateTuesday, December 12, 2023
Registration Number7243677
Registration DateTuesday, December 12, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 4, 2022

Trademark Statements


Goods and ServicesPromoting healthcare professionals' awareness of the benefits of botulinum toxin and dissemination of advertisements and consumer product information relating to botulinum toxin via print, audio, video, digital, on-line medium, and electronic mail; Providing business information about the administration of patient reimbursement programs designed to assist patients regarding medical treatment payment plan options; assistance to patients regarding treatment payment plan options, namely, business administration of patient reimbursement programs; providing a website via a global computer network featuring consumer information and comprehensive content being consumer product information in the fields of neurology, dermatology and urology; distribution of samples for trial purposes in the field of neurology, dermatology and urology
Goods and ServicesProviding resources in the nature of health information for healthcare professionals relating to all approved indications of therapeutic treatments and injection instruction in the fields of neurology and urology

Classification Information


International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateThursday, November 18, 2021
Primary Code035
First Use Anywhere DateSaturday, January 19, 2019
First Use In Commerce DateSaturday, January 19, 2019

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, November 18, 2021
Primary Code044
First Use Anywhere DateSaturday, January 19, 2019
First Use In Commerce DateSaturday, January 19, 2019

Trademark Owner History


Party NameAllergan, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNorth Chicago, IL 60064

Party NameAllergan, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Chicago, IL 60064

Party NameAllergan, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Tuesday, December 12, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, December 12, 2023REGISTERED-PRINCIPAL REGISTER
Thursday, November 9, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Wednesday, November 8, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, November 8, 2023EXAMINER'S AMENDMENT ENTERED
Wednesday, November 8, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, November 8, 2023EXAMINERS AMENDMENT E-MAILED
Wednesday, November 8, 2023SU-EXAMINER'S AMENDMENT WRITTEN
Wednesday, November 1, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 1, 2023NON-FINAL ACTION E-MAILED
Wednesday, November 1, 2023SU - NON-FINAL ACTION - WRITTEN
Tuesday, May 16, 2023STATEMENT OF USE PROCESSING COMPLETE
Friday, April 21, 2023USE AMENDMENT FILED
Wednesday, May 10, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, April 21, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, November 29, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 4, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 4, 2022PUBLISHED FOR OPPOSITION
Wednesday, September 14, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, September 1, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 30, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 29, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 29, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, June 7, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, June 7, 2022FINAL REFUSAL E-MAILED
Tuesday, June 7, 2022FINAL REFUSAL WRITTEN
Monday, May 16, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, May 16, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, May 16, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, November 29, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, November 29, 2021NON-FINAL ACTION E-MAILED
Monday, November 29, 2021NON-FINAL ACTION WRITTEN
Wednesday, November 24, 2021ASSIGNED TO EXAMINER
Thursday, November 18, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED